Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark M Pomerantz, M.D.

Co-Author

This page shows the publications co-authored by Mark Pomerantz and Adam Kibel.
Connection Strength

0.402
  1. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
    View in: PubMed
    Score: 0.183
  2. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr; 2(4):444-456.
    View in: PubMed
    Score: 0.060
  3. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87.
    View in: PubMed
    Score: 0.059
  4. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021 03; 19(3):475-484.
    View in: PubMed
    Score: 0.058
  5. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.